GlassScriptPhysician profile
Alan L Spielberg
NPI 1164554622
$3,812.57
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2021: $440 · 2022: $1,047 · 2023: $1,194 · 2024: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,652.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $434.19 | 2021-2024 | Fetroja |
| Melinta Therapeutics, LLC | $432.99 | 2021-2024 | Kimyrsa, Vabomere, Orbactiv |
| Janssen Pharmaceuticals, INC | $402.90 | 2019-2024 | Xarelto |
| Intercept Pharmaceuticals, INC. | $335.29 | 2021-2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $326.09 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Abbvie INC. | $297.47 | 2019-2024 | Skyrizi, Rinvoq, Teflaro |
| Celgene Corporation | $188.24 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $178.57 | 2022-2024 | Stelara, Remicade, Simponi |
| Janssen Scientific Affairs, LLC | $138.45 | 2019-2021 | |
| Gilead Sciences, INC. | $130.95 | 2023-2024 | |
| Dova Pharmaceuticals | $125.00 | 2019 | |
| Ferring Pharmaceuticals INC. | $108.98 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $103.54 | 2021-2024 | Dupixent |
| Pfizer INC. | $99.42 | 2022-2023 | |
| La Jolla Pharmaceutical Company | $83.61 | 2023-2024 | Xerava |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $80.61 | 2021-2023 | Talicia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.74 | 2022-2024 | Jardiance |
| Ardelyx, INC. | $46.28 | 2023 | Ibsrela |
| Daiichi Sankyo INC. | $36.88 | 2019-2022 | |
| Cumberland Pharmaceuticals, INC. | $29.09 | 2023 | Caldolor |
| Braintree Laboratories, INC. | $28.20 | 2019 | |
| Fisher Scientific Company L.L.C. | $27.49 | 2023 | Procalcitonin |
| Allergan, INC. | $26.00 | 2019 | |
| Reprise Biomedical, INC. | $23.46 | 2023 | Miro3d |
| Takeda Pharmaceuticals U.S.A., INC. | $22.21 | 2023 | Gattex |
| Paratek Pharmaceuticals, INC. | $19.92 | 2021 | |
| Echosens North America, INC. | $17.00 | 2023 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Spielberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.